Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.28: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled/resistant hypertension and related cardiorenal conditions. An NDA was submitted December 2025 with a PDUFA date of December 22,... Read more
Sell if holding. Engine safety override at $26.28: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductlorundrostat10-K Item 1A: 'We currently depend entirely on the success of lorundrostat, which is our only product candidate.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.28: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $24.46. Score 5.1/10, moderate confidence.
Take-profit target: $42.96 (+63.3% upside). Prior stop was $24.46. Stop-loss: $24.46.
Concentration risk — Product: lorundrostat; Quality below floor (1.4 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.0%), High leverage (D/E 1.8).
Mineralys Therapeutics, Inc. trades at a P/E of N/A (forward -14.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover MLYS with a consensus score of 4.2/5. Average price target: $49.
What does Mineralys Therapeutics, Inc. do?Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone...
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled/resistant hypertension and related cardiorenal conditions. An NDA was submitted December 2025 with a PDUFA date of December 22, 2026; the company has no approved products and no revenue to date.